Literature DB >> 16034135

Heparin-binding epidermal growth factor-like growth factor inhibits cytokine-induced NF-kappa B activation and nitric oxide production via activation of the phosphatidylinositol 3-kinase pathway.

Veela B Mehta1, Gail E Besner.   

Abstract

NO produced by inducible NO synthase (iNOS) has been implicated in various pathophysiological processes including inflammation. Therefore, inhibitors of NO synthesis or iNOS gene expression have been considered as potential anti-inflammatory agents. We have previously demonstrated that heparin-binding epidermal growth factor (EGF)-like growth factor (HB-EGF) decreases proinflammatory cytokine IL-8 and NO production in cytokine-stimulated intestinal epithelial cells by interfering with the NF-kappaB signaling pathway. However, the upstream signaling mechanisms involved in these responses have not yet been defined. In this report, we show that in intestinal epithelial cells, HB-EGF triggered PI3K-dependent phosphorylation of Akt. Inhibition of PI3K reversed the ability of HB-EGF to block NF-kappaB activation, expression of iNOS, and NO production. Small interfering RNA of PI3K also reversed the inhibitory effect of HB-EGF on iNOS expression. Alternatively, transient expression of constitutively active PI3K decreased NO production by approximately 2-fold more than treatment with HB-EGF alone. This PI3K effect was HB-EGF dependent. Thus, activation of PI3K is essential but not sufficient for decreased NO synthesis. PI3K and HB-EGF act synergistically to decrease NO synthesis. Neither overexpression or inhibition of MEK, Ras, or Akt affected HB-EGF-mediated inhibition of NF-kappaB activation. These data demonstrate that HB-EGF decreases proinflammatory cytokine-stimulated NF-kappaB activation and NO production via activation of the PI3K signaling pathway. These results also suggest that inhibition of NF-kappaB and activation of the PI3K-dependent signaling cascade by HB-EGF may represent key signals responsible for the anti-inflammatory effects of HB-EGF.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16034135     DOI: 10.4049/jimmunol.175.3.1911

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Synergism between Wnt3a and heparin enhances osteogenesis via a phosphoinositide 3-kinase/Akt/RUNX2 pathway.

Authors:  Ling Ling; Christian Dombrowski; Kin Mun Foong; Larisa M Haupt; Gary S Stein; Victor Nurcombe; Andre J van Wijnen; Simon M Cool
Journal:  J Biol Chem       Date:  2010-06-14       Impact factor: 5.157

2.  HB-EGF improves intestinal microcirculation after hemorrhagic shock.

Authors:  Hong-yi Zhang; Andrei Radulescu; Yan Chen; Gail E Besner
Journal:  J Surg Res       Date:  2010-02-11       Impact factor: 2.192

3.  Heparin-binding epidermal growth factor-like growth factor (HB-EGF) preserves gut barrier function by blocking neutrophil-endothelial cell adhesion after hemorrhagic shock and resuscitation in mice.

Authors:  Hong-yi Zhang; Iyore James; Chun-Liang Chen; Gail E Besner
Journal:  Surgery       Date:  2011-12-09       Impact factor: 3.982

4.  Heparin-binding EGF-like growth factor decreases inflammatory cytokine expression after intestinal ischemia/reperfusion injury.

Authors:  Dorothy V Rocourt; Veela B Mehta; Gail E Besner
Journal:  J Surg Res       Date:  2007-02-07       Impact factor: 2.192

5.  Cypermethrin Stimulates GSK3β-Dependent Aβ and p-tau Proteins and Cognitive Loss in Young Rats: Reduced HB-EGF Signaling and Downstream Neuroinflammation as Critical Regulators.

Authors:  Shailendra Kumar Maurya; Juhi Mishra; Sabiya Abbas; Sanghamitra Bandyopadhyay
Journal:  Mol Neurobiol       Date:  2015-01-10       Impact factor: 5.590

Review 6.  Newly Identified Deficiencies in the Multiple Sclerosis Central Nervous System and Their Impact on the Remyelination Failure.

Authors:  Giuseppe Scalabrino
Journal:  Biomedicines       Date:  2022-03-30

Review 7.  iNOS expression in oral and gastrointestinal tract mucosa.

Authors:  Nurullah Keklikoglu; Meltem Koray; Humeyra Kocaelli; Sevtap Akinci
Journal:  Dig Dis Sci       Date:  2008-06       Impact factor: 3.199

8.  Heparin-binding EGF-like growth factor (HB-EGF) therapy for intestinal injury: Application and future prospects.

Authors:  Jixin Yang; Yanwei Su; Yu Zhou; Gail E Besner
Journal:  Pathophysiology       Date:  2013-12-15

9.  Heparin-binding EGF-like growth factor (HB-EGF) promotes cell migration and adhesion via focal adhesion kinase.

Authors:  Yanwei Su; Gail E Besner
Journal:  J Surg Res       Date:  2014-03-03       Impact factor: 2.192

10.  Characteristics of chemokine signatures elicited by EGF and TNF in ovarian cancer cells.

Authors:  Deok-Soo Son; Syeda M Kabir; Yuanlin Dong; Eunsook Lee; Samuel E Adunyah
Journal:  J Inflamm (Lond)       Date:  2013-06-25       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.